SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
Rhea-AI Summary
SCIENTURE (NASDAQ: SCNX) provided a commercial update on ARBLI™, the first FDA-approved ready-to-use oral suspension of losartan, reporting payer and distribution wins that expand access across retail, institutional and managed-care channels.
Key achievements include PBM-led GPO rebates, Institutional GPO deals covering >2,500 facilities, formulary inclusion for >100 million covered lives, a BlinkRx collaboration, reaffirmed REZENOPY™ commercial launch in Q2 2026, and a year-end cash position of approximately $7.0 million after debt reduction.
Positive
- Secured PBM-led GPO rebate agreements supporting broader formulary placement
- Institutional GPO agreements expanding access to >2,500 healthcare institutions
- Formulary inclusion expanding coverage to >100 million covered lives
- Strategic collaboration with BlinkRx to improve patient access and fulfillment
- Year-end cash position of approximately $7.0 million after debt reduction
Negative
- Company cash of approximately $7.0 million may limit runway for multi-product launches
- Internal inconsistency on REZENOPY™ launch timing (Q1 vs Q2 2026) could confuse stakeholders
Key Figures
Market Reality Check
Peers on Argus
SCNX was down 0.4% pre-news, while key peers were mixed: SSY up 9.31%, HKPD down 8.33%, PETS down 3.46%, WGRX down 9.37%, HITI flat. Only WGRX appeared on the momentum scanner (up ~6.05% there), and no peers had same-day headlines, pointing to a stock-specific setup.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 14 | Patent issuance | Positive | -4.5% | Orange Book-listable patent covering REZENOPY™ and highlighting naloxone market size. |
| Dec 22 | Launch update | Positive | -8.6% | Detailed REZENOPY® commercial launch timing and manufacturing readiness in 2026. |
| Dec 10 | Access partnership | Positive | -2.9% | Strategic BlinkRx collaboration to expand national access to Arbli™. |
| Dec 02 | Conference participation | Neutral | +0.1% | Participation in iAccess Alpha virtual investor conference with management presentations. |
| Nov 13 | Earnings and launch | Neutral | -5.5% | Q3 2025 results showing early Arbli™ revenues and planned REZENOPY® launch. |
Recent history shows frequent negative price reactions to operationally positive news, including product launches, partnerships, and patent wins.
Over the past few months, Scienture has focused on launching and expanding access for Arbli™ and preparing REZENOPY™ for commercialization. Key milestones included Q3 2025 results with Arbli-driven revenue growth, a BlinkRx access partnership, and multiple REZENOPY™ updates, including an Orange Book-listable patent and launch timing. Despite these seemingly constructive developments, the stock often moved lower after such announcements, framing today’s commercial and balance sheet update against a backdrop of cautious market reactions.
Regulatory & Risk Context
The company has an active S-3 shelf with multiple recent 424B5 prospectus supplements and an at-the-market equity program referenced in filings, indicating ongoing capacity to issue equity under this registration if management chooses.
Market Pulse Summary
This announcement details wider ARBLI™ access through PBM and institutional GPO agreements, formulary wins covering over 100 million lives, and a reaffirmed Q2 2026 launch for REZENOPY™ into combined markets of roughly $385 million. Management also cites a strengthened balance sheet with about $7.0 million in cash. In context of prior ATM activity under the S-3 shelf, investors may track future financing decisions, ARBLI™ prescription trends, and execution on the REZENOPY™ rollout.
Key Terms
oral suspension medical
losartan potassium medical
naloxone medical
GPO financial
formulary financial
AI-generated analysis. Not financial advice.
Company highlights accelerating access and revenue growth for ARBLI™ and confirms REZENOPY™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to
Outlines Q1 2026 outlook and reports significant balance sheet improvement last quarter
COMMACK, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a commercial update on ARBLI™ (losartan potassium) oral suspension, the first and only FDA-approved ready-to-use oral liquid formulation of losartan, alongside key market access achievements, financial strengthening initiatives, and near-term outlook—including reaffirming its plan to commercially launch REZENOPY™, a life-saving opioid overdose emergency treatment, in the second quarter of 2026.
Over the past four months, Scienture has executed a series of commercial, payer and patient-focused initiatives designed to materially expand access to ARBLI™ across retail, institutional, and managed care channels within the approximately
Key highlights:
- Secured multiple PBM-led GPO rebate agreements, supporting expanded commercial coverage and formulary placement for ARBLI™
- Executed multiple Institutional GPO agreements, expanding U.S. access to more than 2,500 healthcare institutions nationwide
- Achieved formulary inclusion with major national health plans, expanding coverage to over 100 million covered lives
- Established a strategic collaboration with BlinkRx, enhancing patient access, fulfillment, and adherence through a streamlined digital pharmacy and hub service platform
“These milestones significantly expand the commercial opportunity for ARBLI™ and represent an important inflection point in its launch trajectory,” commented Narasimhan Mani, President and co-CEO of Scienture. “By securing GPO agreements, expanding formulary inclusion, and partnering with BlinkRx, we are significantly increasing the number of patients and providers who can readily access ARBLI™.”
Looking ahead to the first quarter of 2026, Scienture expects:
- Continued sequential growth in ARBLI™ prescription volumes and product adoption
- Improved commercial efficiency, as early launch investments translate into recurring demand
- Further expansion of payer and pharmacy engagement, supporting broader patient access across commercial and government sectors
“We are encouraged by the steady progress we’ve made with ARBLI™ since launch,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “The last four months have validated the unmet need for a ready-to-use oral suspension of losartan, and we believe Q1 2026 will reflect the momentum we’ve built across prescriber adoption, distribution, and patient demand.”
Scienture reaffirms its plan to commercially launch REZENOPY™, a life-saving opioid overdose emergency treatment in the second quarter of 2026, representing the Company’s second product launch in the US market for naloxone (IQVIA MAT Dec 2025 of
“Our progress with ARBLI™ has laid the groundwork for a scalable, multi-product commercial platform. With REZENOPY™ planned for launch in the first quarter of 2026, we believe Scienture is entering its next phase of growth. Importantly, during Q4 2025, we fundamentally strengthened our balance sheet through a substantial reduction in outstanding debt and a meaningful improvement in our cash resources . As of December 31, 2025, the Company had a cash position of approximately
About ARBLI™
ARBLI™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. ARBLI™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, ARBLI™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, ARBLI™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. ARBLI™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.
ARBLI™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. ARBLI™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.
INDICATION
ARBLI™ is an angiotensin II receptor blocker (ARB) indicated for:
- Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
- Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
- Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
IMPORTANT SAFETY INFORMATION
- Do not take ARBLI™ when pregnant. When pregnancy is detected, discontinue ARBLI™ as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ARBLI™ can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
- Do not co-administer ARBLI™ with aliskiren in patients with diabetes. Avoid use of aliskiren with ARBLI™ in patients with renal impairment (GFR <60 mL/min).
- Do not administer ARBLI™ in patients with severe hepatic impairment. ARBLI™ has not been studied in patients with severe hepatic impairment.
- The most common adverse reactions are (incidence ≥
2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.
Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.
About Hypertension
Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.
About REZENOPY™
REZENOPY™ (naloxone HCl) Nasal Spray 10mg, is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present.
REZENOPY™ nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray device.
IMPORTANT SAFETY INFORMATION
- Administration: REZENOPY™ nasal spray is for intranasal use only. Seek emergency medical care immediately after use. Administer a single spray into one nostril. If the patient does not respond within 2 to 3 minutes or responds and then relapses into respiratory depression, an additional dose may be given into the other nostril with a new device. Do not administer more than 2 sprays per day. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.
- Contraindications: REZENOPY™ nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.
- Warnings and Precautions:
- Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer additional doses as necessary while awaiting emergency medical assistance.
- Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.
- Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid-dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal.
- Risk of Cardiovascular Effects: Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular effects. These events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar adverse cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.
- Adverse Reactions: The following adverse reactions were observed in a REZENOPY™ nasal spray clinical study: upper abdominal pain, nasopharyngitis, and dysgeusia.
- Storage and Handling: Store REZENOPY™ nasal spray in the blister and cartons provided. Store between 2°C to 25°C (36°F to 77°F). Excursions permitted up to 40°C (104°F). Do not freeze or expose to excessive heat above 40°C (104°F). Protect from light. REZENOPY™ nasal spray may freeze at cold temperatures. If this happens, the device will not spray. If REZENOPY™ nasal spray is frozen and is needed in an emergency, do NOT wait for it to thaw; get emergency medical help right away.
For more detailed information, please refer to the full prescribing information provided by the FDA.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, such as ARBLI™ and REZENOPY™, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.
Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contact:
SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Phone: (866) 468-6535
Email: IR@Scienture.com
FAQ
What commercial progress did SCNX report for ARBLI™ (losartan) on Feb 3, 2026?
How many patients gained coverage for ARBLI™ after SCNX formulary actions?
When will SCNX commercially launch REZENOPY™ (naloxone) and what market does it target?
What is SCNX's reported cash position and balance sheet update as of Dec 31, 2025?
How will SCNX leverage ARBLI™ to support future product launches like REZENOPY™?
